Regulation of dipeptidyl peptidase 4 production in adipocytes by glucose

Código QR

Regulation of dipeptidyl peptidase 4 production in adipocytes by glucose

Siddhartha Shankar Das, Hiroto Hayashi, Taiki Sato, Ren Yamada, Masahiro Hiratsuka, Noriyasu Hirasawa Laboratory of Pharmacotherapy of Life-Style Related Diseases, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Miyagi, Japan Objective: Type 1 and 2 diabetes are characterize...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Das SS, Hayashi H, Sato T, Yamada R, Hiratsuka M, Hirasawa N
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/eea5802a9134434587b41b69a54f9e36
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Inhibition of dipeptidyl peptidase-4: The mechanisms of action and clinical use of vildagliptin for the management of type 2 diabetes
por: Galina Smushkin, et al.
Publicado: (2009)

Emerging Roles of Dipeptidyl Peptidase-4 Inhibitors in Delaying the Progression of Type 1 Diabetes Mellitus
por: Gurgel Penaforte-Saboia J, et al.
Publicado: (2021)

Predictors of the Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Taiwanese Patients with Type 2 Diabetes Mellitus
por: Lin YH, et al.
Publicado: (2019)

Effect of Saxagliptin, a Dipeptidyl Peptidase 4 Inhibitor, on Non-Alcoholic Fatty Liver Disease
por: Chen L, et al.
Publicado: (2020)

Natural dipeptidyl peptidase-IV inhibitor mangiferin mitigates diabetes- and metabolic syndrome-induced changes in experimental rats
por: Suman RK, et al.
Publicado: (2016)

Dipeptidyl peptidase-4 inhibitors as add-on therapy to insulin in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials
por: Wang N, et al.
Publicado: (2019)

Effect of Switching from Linagliptin to Teneligliptin Dipeptidyl Peptidase-4 Inhibitors in Older Patients with Type 2 Diabetes Mellitus
por: Han E, et al.
Publicado: (2020)

Obesity, adipocyte hypertrophy, fasting glucose, and resistin are potential contributors to nonalcoholic fatty liver disease in South Asian women
por: Albracht-Schulte K, et al.
Publicado: (2019)

Impact of glucose excursion and mean glucose concentration in oral glucose-tolerance test on oxidative stress among Japanese Americans
por: Nakanishi S, et al.
Publicado: (2013)

Influence of type-4 dipeptidyl peptidase inhibition on endothelium-dependent relaxation of aortae from a db/db mouse model of type 2 diabetes: a comparison with the effect of glimepiride
por: Woodman OL, et al.
Publicado: (2019)

Two-way crossover comparison of insulin glargine and insulin detemir in basal-bolus therapy using continuous glucose monitoring
por: Abe S, et al.
Publicado: (2011)

Estrogen receptor inhibition enhances cold-induced adipocyte beiging and glucose tolerance
por: Lapid K, et al.
Publicado: (2019)

Frequency of diabetes, impaired fasting glucose, and glucose intolerance in high-risk groups identified by a FINDRISC survey in Puebla City, Mexico
por: Hirales-Tamez O, et al.
Publicado: (2012)

Glucose estimation in the salivary secretion of diabetes mellitus patients
por: Abikshyeet P, et al.
Publicado: (2012)

Exenatide improves glucocorticoid-induced glucose intolerance in mice
por: Ruiying Zhao, et al.
Publicado: (2011)

Morning cortisol is lower in obese individuals with normal glucose tolerance
por: Praveen EP, et al.
Publicado: (2011)

The impact of brief high-intensity exercise on blood glucose levels
por: Adams OP
Publicado: (2013)

Combination of the sodium-glucose cotransporter-2 inhibitor empagliflozin with orlistat or sibutramine further improves the body-weight reduction and glucose homeostasis of obese rats fed a cafeteria diet
por: Vickers SP, et al.
Publicado: (2014)

Self-monitoring of blood glucose in noninsulin-treated type 2 diabetes: an overview
por: Nanne Kleefstra, et al.
Publicado: (2009)

Retrospective study on the efficacy of a low-carbohydrate diet for impaired glucose tolerance
por: Maekawa S, et al.
Publicado: (2014)

Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetes
por: Kim Y, et al.
Publicado: (2012)

Salivary glucose concentration exhibits threshold kinetics in normal-weight, overweight, and obese children
por: Hartman ML, et al.
Publicado: (2014)

The effect of vagal nerve blockade using electrical impulses on glucose metabolism in nondiabetic subjects
por: Sathananthan M, et al.
Publicado: (2014)

Cost effectiveness and cost utility of the noncoding blood glucose meter CONTOUR&reg; TS
por: Przemyslaw Holko, et al.
Publicado: (2011)

Effect of orally administered dipterinyl calcium pentahydrate on oral glucose tolerance in diet-induced obese mice
por: Fuchs D, et al.
Publicado: (2012)

Effects of combination therapy with mitiglinide and voglibose on postprandial plasma glucose in patients with type 2 diabetes mellitus
por: Konya H, et al.
Publicado: (2013)

Randomized, double-blind, placebo-controlled, clinical study on the effect of Diabetinol® on glycemic control of subjects with impaired fasting glucose
por: Evans M, et al.
Publicado: (2015)

Amantadine reduces glucagon and enhances insulin secretion throughout the oral glucose tolerance test: central plus peripheral nervous system mechanisms
por: Fuad Lechin, et al.
Publicado: (2009)

Glucose-lowering therapies, adequacy of metabolic control, and their relationship with comorbid depression in outpatients with type 2 diabetes in a tertiary hospital in Kenya
por: Otieno CFF, et al.
Publicado: (2017)

Effect of Insulin-Regulated FOXC2 Expression in Adipocyte Differentiation and Insulin Resistance
por: Zhang X, et al.
Publicado: (2020)

Kinin B1 and B2 receptor deficiency protects against obesity induced by a high-fat diet and improves glucose tolerance in mice
por: Morais RL, et al.
Publicado: (2015)

Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus
por: Whaley JM, et al.
Publicado: (2012)

Insulin glulisine in the management of diabetes
por: Satoru Yamada
Publicado: (2009)

Sodium–glucose cotransporter-2 inhibitor combination therapy to optimize glycemic control and tolerability in patients with type 2 diabetes: focus on dapagliflozin–metformin
por: Schwartz SS, et al.
Publicado: (2016)

Alogliptin: a new addition to the class of DPP-4 inhibitors
por: Radha Andukuri, et al.
Publicado: (2009)

Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes
por: Kishimoto M
Publicado: (2013)

Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes
por: Gallwitz B
Publicado: (2013)

Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin
por: Bo Ahr&eacute;n
Publicado: (2010)

Current perspectives on the health risks associated with the consumption of advanced glycation end products: recommendations for dietary management
por: Palimeri S, et al.
Publicado: (2015)

Managing diabetic patients with moderate or severe renal impairment using DPP-4 inhibitors: focus on vildagliptin
por: Russo E, et al.
Publicado: (2013)